Focus: Exelixis is an oncology-focused biotechnology company headquartered in Alameda, CA, specializing in small-molecule tyrosine kinase inhibitors. The company operates as a mid-cap biotech with a highly concentrated revenue base from its flagship product.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Exelixis to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Exelixis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Exelixis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship product generating 100% of company revenue; multi-indication tyrosine kinase inhibitor targeting RET, MET, VEGFR, and 8+ other kinases.
Older formulation of cabozantinib; minimal revenue ($3M) as CABOMETYX tablets have largely displaced it in market.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub